What is it about?
In a previous study (Vaughan et al., JABFM, 2018), we found that oral therapy appeared superior to insulin for individuals with newly diagnosed type two diabetes in underserved settings in terms of glycemic control and Emergency Room visits. In this study, we analyzed the types of oral medications available to underserved settings and their optimal regimens.
Featured Image
Why is it important?
Low-income populations are particularly disadvantaged in diabetes. Not only is diabetes more prevalent in these settings but the medications to treat diabetes are extremely limited when compared to insured populations. In addition, there are variable recommendations regarding initiating monotherapy or dual therapy in patients with newly diagnosed type 2 diabetes. Clear initial strategies are of particular importance in underserved settings where access to care and financial burdens are significant barriers.
Perspectives
We found that initiation of dual therapy resulted in better glycemic control than metformin monotherapy or transitioning therapies (dual to metformin monotherapy or visa versa). This strategy may be preferred for low-income individuals with newly diagnosed type 2 diabetes. We think these are important findings that could improve care upon diagnosis in this vulnerable population.
Elizabeth Vaughan
Baylor College of Medicine
Read the Original
This page is a summary of: Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes, Journal of Primary Care & Community Health, October 2017, SAGE Publications,
DOI: 10.1177/2150131917745760.
You can read the full text:
Contributors
The following have contributed to this page
